← Back to all trials
Recruiting
NCT05717257
Dapagliflozin in Systemic Right Ventricle (DAPA-SERVE)
Conditions: Dapagliflozin Adverse Reaction, Efficacy, Systemic Right Ventricle
Sex: All
Ages: 18 Years – N/A
Phase: PHASE4
Enrollment: 50
Sponsor: Monaldi Hospital
Location: Italy
Summary
The purpose of this study is to describe safety and efficacy of Dapaglifozin in adults patients with a systemic right ventricle (congenitally corrected transposition of the great arteries or transposition of the great arteries following arterial switch procedure) and impaired systolic function of the systemic right ventricle.
Eligibility Criteria
Inclusion Criteria:Age≥18yearsOptimal medical therapy or at least 3monthsSystemic right ventricle ejection fraction≤40%, assessed on echocardiographyExclusion Criteria:Univentricular physiologySystolic blood pressure<90mmHgGlomerular filtration rate(GFR)<30ml/min
Source: ClinicalTrials.gov (NCT05717257). StuddyBuddy aggregates publicly available trial information.
